First Oral Pill for Thalassemia Anaemia Approved by US FDA

-

 


In a landmark development for global blood disorder care, the US Food and Drug Administration has approved the first-ever oral pill for treating anaemia in adults with thalassemia. Health experts have described the decision as a potential game changer that could significantly reduce dependence on lifelong blood transfusions for patients suffering from this inherited condition.

FDA Approval Marks Historic First

The FDA has approved mitapivat, to be marketed under the brand name Aqvesme, for adults with alpha- or beta-thalassemia. It is the first medicine authorised for both transfusion-dependent and non-transfusion-dependent forms of the disease. Until now, thalassemia management has largely relied on regular blood transfusions and iron chelation therapy, often starting from early childhood.

How Mitapivat Works

Mitapivat is a first-in-class pyruvate kinase activator that targets the metabolic dysfunction inside red blood cells. In thalassemia patients, red blood cells are fragile and break down prematurely, leading to chronic anaemia. By improving cellular energy production, mitapivat helps red blood cells survive longer, raises haemoglobin levels, and reduces the need for frequent transfusions.

Expert Views on Clinical Impact

Calling it a path-breaking advance, Dr Satyam Arora of the Postgraduate Institute of Child Health, Noida, said the drug offers the possibility of managing thalassemia with a single oral pill. Haematologist Dr Rahul Bhargava noted that this is the first therapy to directly address the disease at the cellular level rather than only managing its complications, with the potential to transform patient quality of life.



Comments

Post a Comment

Popular posts from this blog

Japan’s Innovative Approach to Artificial Intelligence Legislation

-
Image
  Japan introduced law aimed at encouraging artificial intelligence (AI) research and development. This legislation, known as the Act on the Promotion of Research, Development and Utilisation of Artificial Intelligence-Related Technologies, seeks to position Japan as a leader in the global AI landscape. The law diverges from stringent regulatory frameworks like the European Union’s AI Act, instead promoting an innovation-driven environment. Key Features of Japan’s AI Law The Act establishes an Artificial Intelligence Strategy Headquarters under the Cabinet. This body is responsible for formulating a national Basic Plan for AI. The plan encompasses foundational research, industrial deployment, international collaboration, and public education. The law avoids rigid regulatory frameworks and focuses on enabling innovation and encouraging cooperation among stakeholders. Comparison with the European Union’s AI Act In contrast to Japan’s approach, the EU’s AI Act employs a risk-based cl...
Read more

EMM-Negative Blood Group System

-
Image
  The International Society of Blood Transfusion officially recognised a new blood group system named EMM-negative, also known as Gwada negative. This designation emerged from the unique case of a woman from Guadeloupe who is the only known individual to possess this rare blood type. The discovery puts stress on advancements in transfusion medicine and genetic research. What is Gwada Negative? Gwada negative refers to the EMM-negative blood group system, identified by the absence of the EMM antigen on red blood cells. This antigen is a high-incidence antigen, present in almost all humans. The lack of such a common antigen is medically and has led to the classification of this blood type as the 48th globally recognised system in transfusion science. Discovery Process The identification of the EMM-negative blood type began in 2011 when the woman underwent routine blood tests. Initial attempts to classify her blood were inconclusive due to the lack of technology. In 2019, advancement...
Read more

Non-Binary AI Chip

-
Image
  China has made leap in artificial intelligence with the deployment of non-binary AI chips. This advancement comes from Professor Li Hongge’s team at Beihang University. They have developed a novel computing approach called Hybrid Stochastic Number (HSN) computing. This innovation aims to address critical limitations in conventional computing. About Hybrid Stochastic Number Computing Hybrid Stochastic Number computing merges traditional binary logic with probabilistic logic. Binary systems operate on precise calculations using 1s and 0s, which are energy-intensive. In contrast, stochastic computing uses voltage signal frequencies to represent values, resulting in lower power consumption but often slower performance. The HSN system combines these approaches to achieve a balance of energy efficiency and computational reliability. Addressing Key Limitations in Conventional Chips Two major limitations challenge conventional chips – the power wall and the architecture wall. The power ...
Read more